1Choi BO,Choi IB,Jang HS,et al.Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepa-tocellular carcinoma:preliminary analysis[J].BMC Cancer,2008;8:351.
2Altekruse SF,McGlynn KA,Reichman ME.Hepatocellular carcinoma in-cidence,mortality,and survival trends in the United States from 1975 to 2005[J].J Clin Oncol,2009;27(9):1485-91.
3Bei R,Mizejewski GJ.Alpha fetoprotein is more than a hepatocellular cancer biomarker:from spontaneous immune response in cancer patients to the development of an AFP-based cancer vaccine[J].Curr Mol Med,2011;11(7):564-81.
4Beale G,Chattopadhyay D,Gray J,et al.AFP,PIVKAII,GP3,SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease[J].BMC Cancer,2008;8:200.
7Aapro MS, Martin C, Hatty S. Gemeitabine-a safety review [J]. Anticancer Drugs, 1998,9(3) : 191-201.
8Burris HA 3rd, Moore M J, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial [Jl. J Clin Oncol, 1997,15(6):2403-2413.
9Sail F, Roscher R, Beger HG. Tumor markers in pancreatic cancer: Sensitivity and specificity of CA 19-9 [J]. Hepatogastroenterology, 1989,36(6) : 419-423.
10Halm U, Rohde N, Klapdor R, et al. Improved sensitivity of fuzzy logic based tumor marker profiles for diagnosis of pancreatic carcinoma versus benign pancreatic disease [J]. Anticancer Res, 2000,20(6D) :4957-4960.
